Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis

OBJECTIVES: On July 20, 2012, the European Medicines Agency (EMA) provided a recommendation that limits the long-term use of calcitonin. Based on this recommendation, we investigate the presence or absence of a cancer diagnosis in subjects who participated in the ongoing clinical trial of elcatonin....

全面介紹

Na minha lista:
書目詳細資料
發表在:Osteoporos Sarcopenia
Main Authors: Okamoto, Hiroaki, Shibazaki, Nayumi, Yoshimura, Takeshi, Uzawa, Toyonobu, Sugimoto, Toshitsugu
格式: Artigo
語言:Inglês
出版: Korean Society of Osteoporosis 2020
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7093680/
https://ncbi.nlm.nih.gov/pubmed/32226828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.afos.2020.02.001
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍